17th week of 2022 patent applcation highlights part 10 |
Patent application number | Title | Published |
20220125858 | ANTIBACTERIAL COMPOSITION AGAINST DRUG-RESISTANT BACTERIA OR PRO-INFLAMMATORY BACTERIA - The present invention provides an antibacterial composition against drug-resistant bacteria or pro-inflammatory bacteria containing an intestinal bacterium as an active ingredient, or a pharmaceutical composition for treating, ameliorating, or preventing an infectious disease or an inflammatory disease. | 2022-04-28 |
20220125859 | AGENTS AND METHOD FOR IMPROVIING GUT HEALTH - An improved agent and treatment method for a broad variety of diseases in both animals and humans are disclosed. The agent is an inventive treatment compound comprising a bacterial-based culture. The inventive treatment compound has a positive impact on the gut health of boilers from the earliest stage onward. These benefits are realized through several mechanisms, including improved gut morphology under disease stress. Healthier gut morphology and improved gut integrity result in improved nutrient uptake and growth benefits, both based on consumption of the disclosed inventive treatment compound. The downstream results are improvements in performance parameters related to gut health including altering gut microbes, feed conversion rates, and body weight gains among others. Use of the disclosed treatment compound has the further benefit of avoiding contamination during animal processing because of the reduction in the volume of pathogenic bacteria in the gut. | 2022-04-28 |
20220125860 | PROBIOTIC COMPOSITIONS COMPRISING LACTOBACILLUS REUTERI STRAINS AND METHODS OF USE - The present invention relates to probiotic compositions and methods for increasing animal health. The probiotic compositions include one or more isolated strains of novel | 2022-04-28 |
20220125861 | REDUCING TRIMETHYLAMINE OR TRIMETHYLAMINE-N OXIDE LEVELS IN A SUBJECT - The present disclosure describes probiotic compositions comprising | 2022-04-28 |
20220125862 | COMPOSITION FOR PREVENTING, ALLEVIATING OR TREATING NEURODEGENERATIVE DISEASES, COMPRISING PEDIOCOCCUS INOPINATUS - The present disclosure relates to a composition for preventing, alleviating or treating a neurodegenerative disease, which contains | 2022-04-28 |
20220125863 | COMPOSITIONS FOR TREATING CANDIDIASIS INFECTIONS - The present invention relates to a composition comprising as antifungal active agent at least 2·10 | 2022-04-28 |
20220125864 | METHODS OF TREATING SOLID OR LYMPHATIC TUMORS BY COMBINATION THERAPY - The present invention provides methods for treating an individual having solid or lymphatic tumor comprising local administration to the site of the tumor an infectious agent an immunomodulator (including a combination of immunomodulators). The methods may further comprise local administration to the site of the tumor inactivated tumor cells. Also provided are compositions and kits for the cancer therapy methods. | 2022-04-28 |
20220125865 | Platform Oncolytic Vector for Systemic Delivery - This disclosure provides a modified oncolytic virus that can contain modifications in the viral genome and exogenous nucleic acids coding for proteins. The modified oncolytic virus can be utilized as a platform vector for systemic delivery. | 2022-04-28 |
20220125866 | PHARMACEUTICAL COMPOSITIONS TO ENHANCE PHAGOCYTOSIS WITHOUT INFLAMMATION - The invention relates to a composition comprising a peptide and an immunotherapeutic composition, and a method of inducing phagocytosis without inflammation comprising administering the composition. | 2022-04-28 |
20220125867 | CANNABINOID CONTAINING COMPOSITION, METHODS OF PREPARATION AND USE THEREOF - Solid compositions including a plurality of cannabinoids and methods of preparing such solid compositions are provided. The plurality of cannabinoids in the solid compositions are characterized by a chemical signature which is substantially identical to the chemical signature of cannabinoids in an extract of the | 2022-04-28 |
20220125868 | HEMP COMPOSITIONS AND METHODS OF MAKING THE SAME - The present disclosure provides new beverages and methods of making said beverages from hemp juice, coffee fruit, and oranges. The present disclosure also provides new beverages and methods of making said beverages from hemp juice and coffee fruit juice. The disclosure further relates to the production of a non-water-soluble and water-soluble coffee fruit, hemp juice, and orange powders. | 2022-04-28 |
20220125869 | METHOD FOR OBTAINING OLEOCANTHAL TYPE SECOIRIDOIDS AND FOR PRODUCING RESPECTIVE PHARMACEUTICAL PREPARATIONS - The present invention relates to the method for obtaining in pure form or as a mixture of the bioactive diol forms of the main secoiridoid phenols present in olive oil and certain isomeric forms or derivatives thereof. Specifically, it relates to the production process of S-(E)-oleocanthadiol, S-(E)-oleaceinediol, 5S-(E)-oleomissionadiol, 5S-(E)-oleokoronadiol, oleuropeinediol and ligstrodiol and their corresponding polyethylene glycol hemiacetals through extraction of specifically selected olive oil with polyethylene glycol and then treated with water. It also relates to the pharmaceutical preparations containing the above substances in various combinations and the therapeutic properties of these preparations for the treatment of cancer, degenerative diseases of the central nervous system, diabetes, hyperlipidemia, inflammatory diseases and the prevention of creation of atherosclerotic plaques and thrombi. | 2022-04-28 |
20220125870 | METHOD FOR PRODUCING PLANT MATERIALS HAVING REDUCED VARIANCE - The invention relates to a method for producing standardised or quantified plant materials having reduced variance in phytonutrients, in particular from medicinal plants, using a mixture calculator. | 2022-04-28 |
20220125871 | Compositions And Methods For Nutritional Supplements - Compositions and methods are presented in which a plurality of chemically distinct polyphenols inhibit multiple enzymes in pathways associated with health and healthy ageing. Preferred compositions are derived from colored plant materials that are commonly found in the Mediterranean diet and provide the biochemical basis for the health benefits of the Mediterranean diet. Notably, the enzyme inhibition observed with the combined polyphenols was synergistic with respect to not one but a significant number of enzymes in the pathways associated with health and healthy ageing, thus providing an amplified desirable effect. | 2022-04-28 |
20220125872 | POLYHERBAL TRANSDERMAL PATCH FOR PAIN MANAGEMENT AND ITS PROCESS OF PREPARATION - The present invention relates to composition of polyherbal transdermal patch comprising combination of natural herbal extracts as active ingredients and pharmaceutically acceptable excipients. The present invention relates to composition of polyherbal transdermal patch comprising combination of natural herbal extracts includes boswellia extract, evening primrose oil, blackcurrant seed oil, Ginger, Licorice, Cats claw and Devil's claw and other pharmaceutically acceptable excipients. The present invention also relates to composition of polyherbal transdermal patch comprising boswellia extract, evening primrose oil, blackcurrant seed oil, Ginger, Licorice, Cats claw and Devil's claw as natural herbal ingredients and pharmaceutically acceptable excipients for the treatment/management of pain. The present invention also relates to an efficient process for the preparation of polyherbal transdermal patch by using hot-melt coating technique (HMC), comprising the steps of melting, mixing, coating, laminating, cutting, pouching and labelling. | 2022-04-28 |
20220125873 | ANTIMICROBIAL PEPTIDES - Antimicrobial peptides (AMPs), small compounds that often exhibitbroad spectrum antimicrobial activity, are garnering interest as potential therapeutics against antibiotic-resistant bacterial pathogens. Development of new AMPs is arduous due to the practical limitations of classical protein-based discovery approaches. A high throughput bioinformatics approach is described which is able to confirm identification of known AMPs from the North American bullfrog ( | 2022-04-28 |
20220125874 | METHODS OF USE OF SOLUBLE CD24 FOR TREATING SYSTEMIC LUPUS ERYTHEMATOSUS - The present invention relates to the use of a CD24 protein for treating Systemic Lupus Erythematosus (Lupus, SLE). | 2022-04-28 |
20220125875 | AAV-MEDIATED GENE THERAPY RESTORING THE OTOFERLIN GENE - The present inventors report here, in the DFNB9 mouse model (OTOF knock-out mice), the first proof-of-principle that cochlear delivery of a fragmented cDNA via a dual-AAV vector approach can effectively and long-lastingly correct the profound deafness phenotype of these mice when administered well after their auditory system has matured (P30). The present invention therefore concerns a vector system that allows the expression of the full-length Otoferlin polypeptide, or of a functional fragment thereof, in inner hair cells, for use for treating patients suffering from DFNB9 deafness or preventing DFNB9 deafness in patients having DFNB9 mutations, wherein said patients are patients having a developed and mature auditory system, such as new born babies, toddlers, infants, teenagers or adults. | 2022-04-28 |
20220125876 | A METHOD OF IMMUNE MODULATION BY MODULATING ABCF1 - The present invention relates to methods of immune modulation. In particular, the present invention relates to regulation of inflammation and immune responses by modulation of ABCF1. Modulation of ABCF1 may be useful in the treatment of sepsis, autoimmune diseases, cancer or infections. | 2022-04-28 |
20220125877 | METHOD FOR TREATING COLORECTAL CANCER - The present invention relates to a method for treating colorectal cancer (CRC); this present invention confirms that KRAS mutation CRC patients benefit from metformin more significantly for the first time and further confirms that the down-regulated expression of MATE1 in the discharge passage of metformin is a key mechanism for the sensitivity of KRAS mutation CRC cells to metformin. The transcriptional level of MATE1 is decreased and the concentration of metformin in tumor cells is increased by upregulating the transmethylase DNMT1 and down-regulating the demethylase TET1/2, and thereby the inhibiting effect of metformin on tumor cell proliferation is enhanced. The present invention provides a novel thinking and method for the treatment of colorectal cancer, which has profound significance and is worth popularizing energetically. | 2022-04-28 |
20220125878 | Compositions and Methods for Preventing the Interaction Between SARS-COV-2 and L-Sign - The present invention includes methods for treating and/or preventing a viral or virally-induced tissue dysfunction or failure in a patient comprising administering an inhibitor of SARS-CoV-2 binding to L-SIGN in an amount effective to treat the viral or virally-induced tissue dysfunction or failure of cells do not express ACE2. | 2022-04-28 |
20220125879 | ALBUMIN-BOUND COMPOSITION INCLUDING LRRD2 OF SLIT3 PROTEIN FOR PREVENTION OR TREATMENT OF BONE-RELATED DISEASES - The present invention relates to a composition comprising albumin-bound LRRD2 of the SLIT3 protein for prevention or treatment of bone-related diseases. | 2022-04-28 |
20220125880 | METHOD FOR TREATING CHECKPOINT INHIBITORS INDUCED ADVERSE EVENTS - The invention relates to the use of CTLA | 2022-04-28 |
20220125881 | METHOD FOR PREPARING A BONE PROTEIN PREPARATION AND A BONE PROTEIN PREPARATION - The present invention provides a method for preparing a bone protein preparation which contains for example growth factors. The present invention also provides a bone protein preparation obtained by the method and paste, putty, pellet, disc, block, granule, osteogenic device or pharmaceutical composition containing said bone protein preparation. | 2022-04-28 |
20220125882 | METHODS AND COMPOSITIONS FOR TREATMENT OF CANCER - In one aspect, methods and compositions are provided for treating a neoplasia such as a solid tumor, the methods and composition comprising a) a granulocyte colony-stimulating factor (G-CSF) compound; and b) a monoacetyl diacylglycerol compound such as 1-palmitoyl-2-linoleoyl-3-acetylglycerol (PLAG). | 2022-04-28 |
20220125883 | METHOD OF TREATING CANCER - There is provided with a method of treating cancer. A chemokine is administered in combination with performing a hyperthermia on the cancer. This improves an effect of the hyperthermia on the cancer. Performing the hyperthermia includes locally heating the cancer. | 2022-04-28 |
20220125884 | INTERLEUKIN-2-Fc FUSION PROTEINS AND METHODS OF USE - Provided are serum half-life extended-IL-2 variant (IL-2v) heterodimers having reduced binding to the IL2Rα (CD25) subunit. In particular, Fc-IL-2v heterodimers are provided and methods for making and using, e.g. for enhancing an immune response, e.g. in the prevention and treatment of viral infections and cancer. | 2022-04-28 |
20220125885 | GLUCAGON ANALOG AGONISTS AND METHODS OF USING THE SAME - Glucagon analog agonist compounds are provided herein that have improved solubility, as well as improved chemical and physical stabilities, when compared to native, human glucagon. Also provided are pharmaceutical compositions including such glucagon analog agonist compounds, as well as methods of using the same for treating hypoglycemia, especially severe hypoglycemia. | 2022-04-28 |
20220125886 | CO-FORMULATIONS OF AMYLIN ANALOGUES WITH INSULIN ANALOGUES FOR TREATMENT OF DIABETES - Compositions and methods for treating diabetes are disclosed. In particular, the invention relates to co-formulations of amylin analogues with insulin analogues for treatment of diabetes. | 2022-04-28 |
20220125887 | USES OF PTHrP ANALOGUE IN REDUCING FRACTURE RISK - Disclosed herein are PTHrP or analogues thereof, such as abaloparatide, for preventing or reducing bone fractures in subjects in need thereof, as well as methods of using PTHrP or analogues thereof to prevent or reduce bone fractures. Also disclosed are PTHrP or analogues thereof, such as abaloparatide, for increasing BMD and/or TBS in subjects in need thereof, as well as methods of using PTHrP or analogues thereof to increase BMD and/or TBS. | 2022-04-28 |
20220125888 | SUSTAINED-RELEASE LIPID PREFORMULATION ANDPHARMACEUTICAL COMPOSITION FOR SUSTAINED-RELEASEINJECTION IN FORM OF LIPID SOLUTION CONTAINING SAME - Provided is a sustained-release lipid pre-concentrate in the form of a lipid solution, including an unsaturated fatty acid having 14 to 20 carbon atoms (C14˜C20); a phospholipid; and α-tocopherol acetate, wherein the sustained-release lipid pre-concentrate is free of diacyl glycerol and sorbitan unsaturated fatty acid ester; and forms a liquid crystal in an aqueous medium. Further provided is a sustained-release injectable pharmaceutical composition in the form of a lipid solution, including the pre-concentrate and a pharmacologically active substance, wherein the sustained-release injectable pharmaceutical composition is free of diacyl glycerol and sorbitan unsaturated fatty acid ester. | 2022-04-28 |
20220125889 | COMPOSITION COMPRISING ALBUMIN-COUPLED SLIT3 LRRD2 FOR PREVENTION OR TREATMENT OF MUSCLE DISEASE - The present invention relates to a composition comprising albumin-bound Slit3 LRRD2 for prevention or treatment of a muscle disease, and more particularly provides a fusion protein comprising albumin-bound Slit3 LRRD2, a nucleic acid molecule encoding the fusion protein, a recombinant vector comprising the nucleic acid molecule, a transformant comprising the recombinant vector, a method for preparing a fusion protein using the transformant, a composition comprising the fusion protein for prevention or treatment of a muscle disease, and a composition comprising the fusion protein for improving the in vivo half-life of LRRD2 of the Slit 3 protein. | 2022-04-28 |
20220125890 | TREATMENT AND DETECTION OF INHERITED NEUROPATHIES AND ASSOCIATED DISORDERS - The present disclosure relates to methods of detecting and treating inherited neuropathy. | 2022-04-28 |
20220125891 | METHOD FOR TREATING AND/OR PREVENTING REGNASE-1-RELATED DISEASE - The present invention found that, for example, inhibiting phosphorylation of a Ser residue in Regnase-1 is effective in treating and/or preventing diseases. The invention also found that, for example, inhibiting the binding of Regnase-1 with at least one factor selected from the group consisting of TBK1, IKKi, Act-1, IKK, and IRAK is effective in treating and/or preventing diseases. | 2022-04-28 |
20220125892 | GLUCOCEREBROSIDASE POLYPEPTIDES - The present invention provides glucocerebrosidase preparations, uses thereof as well as methods employing such, particularly in therapy of conditions involving glucocerebrosidase deficiency, such as Gaucher disease and glucocerebrosidase-associated alpha-synucleinopathies. | 2022-04-28 |
20220125893 | METHODS FOR TREATING ARTHRITIS USING SPL-108 PEPTIDE - This invention relates to methods of treatment for arthritis using SPL-108 polypeptide. In particular, this invention relates to such methods of treatment by the administration of an SPL-108 polypeptide (also known as A6 peptide, a CD44 modulating peptide) or a variant thereof alone or in combination with a standard-of-care treatment for arthritis to alleviate and/or prevent symptoms of arthritis and/or to avoid side effects commonly associated with treating arthritis. Such methods of the present invention are used to treat inflammatory conditions such as rheumatoid arthritis, osteoarthritis, reactive arthritis, and/or psoriatic arthritis. | 2022-04-28 |
20220125894 | METHODS FOR TREATING INTRACRANIAL HEMORRHAGE AND ASSESSING EFFICACY - The present disclosure relates to compositions and methods useful for assessing the efficacy in a patient having suffered from intracranial hemorrhage while undergoing an anticoagulation treatment with a factor Xa (fXa) inhibitor. The method can include administering to the patient a fXa derivative that has reduced catalytic activity as compared to the wild-type fXa protein, is capable of binding to the factor Xa inhibitor and cannot assemble into a prothrombinase complex; obtaining a blood sample from the patient following the administration; and measuring an anti-fXa activity in the sample, wherein the anti-fXa activity reflects the hemostatic efficacy in the patient. Once the assessment is made, suitable medical interventions can be implemented. | 2022-04-28 |
20220125895 | SAFE AND EFFECTIVE BETA-LACTAMASE DOSING FOR MICROBIOME PROTECTION - The present invention relates to, inter alia, safe and effective doses of a beta-lactamase for, e.g. microbiome protection. | 2022-04-28 |
20220125896 | COMPOSITIONS AND METHODS FOR TREATMENT OF HOMOCYSTINURIA - Provided are compositions and methods for enzyme replacement therapy using modified human cystathionine beta synthase (CBS) in the treatment of homocystinuria and related diseases and disorders. | 2022-04-28 |
20220125897 | Antithrombin-III Treatment of Traumatic Brain Injury - The present invention is based on the discovery that a composition comprising antithrombin-III can reduce in vivo recruitment of leukocytes and can reduce local microvascular permeability in subjects following severe traumatic brain injury (TBI). In some aspects, treatment of subjects with AT-III following a TBI improves neurocognitive recovery, in particular, with respect to learning. The present disclosure relates to a composition comprising a therapeutically effective amount of antithrombin-III for treating TBI. In another aspect, the present disclosure relates to a method of treating a TBI in a subject by administering to the subject a composition comprising a therapeutically effective amount of antithrombin-III. | 2022-04-28 |
20220125898 | PAR2 MODULATION AND METHODS THEREOF - Provided herein are methods of identifying an agent that activates a protease-activated receptor 2 (PAR2)intracellularly. Also provided are isolated mutant PAR2 polypeptides, isolated polynucleotides encoding the mutant PAR2 polypeptides, vectors comprising the isolated polynucleotides, and host cells comprising the vectors. | 2022-04-28 |
20220125899 | RNA CANCER VACCINES - The present application is related to a method of treating a cancer by administering to a human subject multiple doses of a mRNA cancer vaccine formulated as a lipid nanoparticle wherein the cancer vaccine comprises one or more mRNAs each having one or more open reading frames encoding 3-50 peptide epitopes, and wherein each of the peptide epitopes are portions of personalized cancer antigens or portions of cancer hotspot antigens. The present application further relates to a method of treating cancer by combining anti-cancer immunotherapy with the administration of the aforementioned mRNA cancer vaccine. | 2022-04-28 |
20220125900 | NEOANTIGENS IN CANCER - The invention provides improved strategies, prognostic indicators, compositions, and methods for producing personalized neoplasia vaccines. More particularly, embodiments of the present disclosure relate to the identification of neoplasia-specific neo-epitopes to predict survival and to identify and design subject-specific neo-epitopes, further assessing the identified neo-epitopes encoded by said mutations to identify neo-epitopes that are known or determined, or predicted to engage regulatory T cells and/or other detrimental T cells (including T cells with potential host cross-reactivity and/or anergic T cells), and excluding such neo-epitopes that are known, determined, or predicted) to engage regulatory T cells and/or other detrimental T cells (including T cells with potential host cross-reactivity and/or anergic T cells) from the subject-specific neo-epitopes that are to be used in personalized neoplasia vaccines. The present disclosure further relates to a novel ranking system for determining the optimal subject-specific neo-epitopes that are to be used in personalized neoplasia vaccines. | 2022-04-28 |
20220125901 | TREATMENT OF CANCER USING RECALL ANTIGENS DELIVERED BY ATTENUATED BACTERIA - Methods, pharmaceutical compositions and vaccines comprising an attenuated bacteria that expresses a recall antigen are disclosed for treatment of cancer. | 2022-04-28 |
20220125902 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST PROSTATE CANCER AND OTHER CANCERS - The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules. | 2022-04-28 |
20220125903 | METHODS FOR IMPROVING THE EFFICACY OF A SURVIVIN THERAPEUTIC IN THE TREATMENT OF TUMORS - The present application relates generally to methods for treating tumors, and in particular to methods for improving the efficacy of a survivin therapeutic in the treatment of tumors by improving survivin specific T cell infiltration in tumor. | 2022-04-28 |
20220125904 | METHODS OF CANCER TREATMENT USING TUMOR ANTIGEN-SPECIFIC T CELLS - The present application provides methods of preparing tumor antigen-specific T cells comprising enriching activated T cells from a first co-culture comprising a first population of antigen-loaded dendritic cells loaded and a population of T cells, and co-culturing the enriched activated T cells with a second population of antigen-loaded dendritic cells. Also provided are methods of treating cancer in an individual using the tumor antigen-specific T cells, pharmaceutical compositions and kits for cell-based cancer immunotherapy. | 2022-04-28 |
20220125905 | MESOTHELIN CARS AND USES THEREOF - The presently disclosed subject matter provides polypeptide compositions comprising a chimeric antigen receptor (CAR) that targets mesothelin; and a dominant negative form of programmed death 1 (PD-1 DN). Also provided are immunoresponsive cells comprising such polypeptide compositions and uses of the polypeptide compositions and immunoresponsive cells for treatment, e.g., for treating solid tumors. | 2022-04-28 |
20220125906 | TREATMENT OF BENIGN NERVOUS SYSTEM TUMORS USING ATTENUATED SALMONELLA TYPHIMURIUM - Compositions and methods for the treatment of benign nervous system tumors including schwannomas using attenuated | 2022-04-28 |
20220125907 | OPTIMIZED CELL-FREE SYNTHESIS OF INVASION PLASMID ANTIGEN B AND RELATED COMPOSITIONS AND METHODS OF USE - The present disclosure provides a cell-free method for synthesizing an Invasion Plasmid Antigen B (IpaB) antigen associated with a | 2022-04-28 |
20220125908 | HONEYBEE COMMENSAL SNODGRASSELLA ALVI VACCINE AGAINST PATHOGENIC NEISSERIACEAE - Embodiments herein include an attenuated live vaccine composition for protection against | 2022-04-28 |
20220125909 | CHIMERIC RSV AND HMPV F PROTEINS, IMMUNOGENIC COMPOSITIONS, AND METHODS OF USE - This disclosure relates to a chimeric respiratory syncytial vims encoding a chimeric RSV and hMPV F protein and uses of the chimeric virus or components therein in a vaccine. In certain embodiments, this disclosure relates to a live attenuated vaccine comprising an RSV backbone substituting the F proteins of RSV, for a chimeric RSV and hMPV F protein. | 2022-04-28 |
20220125910 | METHODS AND COMPOSITIONS FOR INDUCING PROTECTIVE IMMUNITY AGAINST RSV INFECTION - Compositions, vaccines and methods using adenovirus vectors for inducing protective immunity against a respiratory syncytial virus (RSV) infection are described. | 2022-04-28 |
20220125911 | Paramyxovirus and uses thereof - The present invention relates to a novel feline paramyxovirus. The paramyxovirus of the present invention is a (−)ssRNA virus and has in one aspect a genome which is complementary to the nucleic acid according to SEQ ID NO:1 or SEQ ID NO:8. The invention further relates to corresponding nucleic acids and polypeptides, antibodies and vaccines. Further, the invention relates to medical uses and diagnostic methods concerning the paramyxovirus of the invention. | 2022-04-28 |
20220125912 | VACCINE AGAINST RSV - Compositions including a recombinant respiratory syncytial virus (RSV) Fusion (F) polypeptide that is stabilized in the pre-fusion conformation are described. The RSV F polypeptide includes at least one mutation as compared to a wild type RSV F polypeptide and the at least one mutation is a) a mutation of the amino acid aspartic acid (D) on position 486, b) a mutation of the amino acid aspartic acid (D) on position 489, or c) a mutation of the amino acid serine (S) on position 398 and/or the amino acid lysine (K) on position 394. Compositions including an isolated nucleic acid molecule encoding the stable RSV F polypeptides are also described. | 2022-04-28 |
20220125913 | SYNTHETIC PEPTIDES, AMINO-ACID SEQUENCES, AND COMPOSITIONS USEFUL FOR SARS-CoV-2 DETECTION AND COVID-19 PREVENTION - The present invention provides designing and synthesizing monomer, polymer, or multimer and formulations of amino-acid chains and peptides from SARS-CoV-2 which are subjected to specific peptide-backbone modifications after being screened by a rational selection which has proven to be highly antigenic and immunogenic useful for human antibody detection and stimulation in higher vertebrates as vaccine components. The so obtained peptides have a common functional motif of formula I: | 2022-04-28 |
20220125914 | CORONAVIRUS VACCINE FORMULATIONS - Disclosed herein are coronavirus Spike (S) proteins and nanoparticles comprising the same, which are suitable for use in vaccines. The nanoparticles present antigens from pathogens surrounded to and associated with a detergent core resulting in enhanced stability and good immunogenicity. Dosages, formulations, and methods for preparing the vaccines and nanoparticles are also disclosed. | 2022-04-28 |
20220125915 | Recombinant Non-Pathogenic Marek's Disease Virus Constructs Encoding Infectious Laryngotracheitis Virus and Infectious Bursal Disease Virus Antigens - The present invention discloses novel recombinant multivalent non-pathogenic Marek's Disease virus constructs that encode and express both Infectious Laryngotracheitis Virus protein antigens and an Infectious Bursal Disease virus protein antigen, and methods of their use in poultry vaccines. | 2022-04-28 |
20220125916 | PEANUT HYPOALLERGENIC FORMULATIONS FOR DETERMINING THE RISK OF ANAPHYLAXIS - The present disclosure provides a method for stratifying subjects with respect to their relative risk of developing anaphylaxis upon the ingestion of a peanut allergen. The method is based on the differential allergic response of the subject in a skin prick test using an Ara h 2 hypoallergenic formulation (which substantially lacks or is devoid of Ara h 8). The present disclosure also provides a peanut hypoallergenic formulation, which can be used as a reagent during the skin prick test, as an oral immunotherapy reagent or as a food product. The present disclosure further provides a process for making the peanut hypoallergenic formulation. | 2022-04-28 |
20220125917 | METHODS FOR PREPARING ALUMINUM PRECIPITATE COMPOUNDS FOR USE IN THERAPEUTICS AND VACCINES - The invention relates to means and methods for preparing aqueous composition comprising aluminium and a protein said composition comprising less than 700 ppm heavy metal on the basis of weight with respect to the aluminium content. The invention further relates to aqueous compositions comprising a protein and an aluminium-salt, said composition comprising less than 350 ppb heavy metal based on the weight of the aqueous composition. | 2022-04-28 |
20220125918 | ADJUVANT COMPOSITION FOR A VACCINE - An adjuvant composition for a vaccine includes one or more substantially isoparaffinic hydrocarbon oils having C17 and/or C18 isoparaffins, and one or more surfactants. A vaccine includes the adjuvant composition. | 2022-04-28 |
20220125919 | ALPHAVIRUS NEOANTIGEN VECTORS AND INTERFERON INHIBITORS - Disclosed herein are vectors that include alphavirus-based expression platforms. Also disclosed are methods associated with the alphavirus-based expression platforms and co-administration of an inhibitor of Type I interferon signaling. | 2022-04-28 |
20220125920 | COMBINATION THERAPY FOR TREATMENT OF CORONARY ARTERY DISEASE - An effective combined dose of an anti-CD47 agent and an anti-TNFα agent is administered to the subject in a dose and for a period of time effective to stabilize, prevent or reduce atherosclerotic plaque in the individual. | 2022-04-28 |
20220125921 | ANTIBODY-CONTAINING FORMULATIONS - In one non-limiting embodiment, the present disclosure relates to lyophilized formulations containing an IL-31 antagonist (for example, an anti-IL-31RA antibody) as an active ingredient, the lyophilized formulations further containing arginine and/or a salt thereof and sucrose and/or trehalose. In another non-limiting embodiment, the present disclosure relates to solution formulations containing an IL-31 antagonist as an active ingredient, the solution formulations further containing arginine and/or a salt thereof. In other non-limiting embodiments, the present disclosure relates to methods for stabilizing an antibody (for example, an anti-IL-31RA antibody) in an antibody-containing formulation, methods for suppressing antibody aggregation (aggregate formation) in an antibody-containing formulation, and methods for reducing components with charge heterogeneity in an antibody-containing formulation, the methods being characterized in that the formulation is prepared to contain arginine and/or a salt thereof, and/or sucrose and/or trehalose. | 2022-04-28 |
20220125922 | Photosensitive Dyes and Method of Using Said Dyes - A bandage and a method of treating a wound with the bandage is provided. The method includes the steps of applying a photosensitive dye to the wound; covering the wound with a bandage; and applying a light to the dye such that the dye generates a reactive oxygen species. | 2022-04-28 |
20220125923 | NOVEL AZOBENZENE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE FOR THERAPEUTIC TREATMENT ASSOCIATED WITH IONIZING RADIATIONS - The present invention relates to new ionizing radiation-activatable derivatives, their preparation process and their therapeutic uses. | 2022-04-28 |
20220125924 | GRANULATED ANTHELMINTIC PREPARATIONS AND DELIVERY SYSTEMS - The present invention relates to anthelmintic compositions comprising two or more anthelmintic active agents selected from one or more of the following groups; imidazothiazoles such as levamisole, benzimidazoles such as oxfendazole, or fenbendazole, macrocylic lactones such as ivermectin or avermectin, salicylanilides, and praziquantel. The composition being in the form of stable granules that are readily dispersible in water so as to provide a homogenous mixture of the anthelmintic agents suitable for administration. Methods of preparing the composition are also described. | 2022-04-28 |
20220125925 | MEDIUM CHAIN TRIGLYCERIDE FORMULATIONS WITH IMPROVED BIOAVAILABILITY AND METHODS RELATED THERETO - The invention relates compositions of medium chain triglycerides (MCTs), and to methods for treatment with such compositions to treat conditions associated with reduced neuronal metabolism, for example Alzheimer's disease. | 2022-04-28 |
20220125926 | Drug Delivery System - The present invention relates to a drug delivery system and methods of using the delivery system, particularly a delivery system for transporting pharmaceutically active agents across, for example, the skin, the surface of the eye or mucosal membranes. The drug delivery system comprises a pharmaceutically effective moiety and a polyamine or amine moiety, wherein the polyamine or amine moiety does not comprise two or more contiguous basic amino acid residues. The drug delivery system may be provided for use as a medicament, or for use in the treatment of a disease or condition selected from eye disease, burns, infection, and trauma. The invention also provides a method comprising administering a pharmaceutically effective amount of the drug delivery system of the invention to a patient in need thereof. | 2022-04-28 |
20220125927 | BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS - The present invention relates to a cationic lipid having one or more biodegradable groups located in a lipidic moiety (e.g., a hydrophobic chain) of the cationic lipid. These cationic lipids may be incorporated into a lipid particle for delivering an active agent, such as a nucleic acid. The invention also relates to lipid particles comprising a neutral lipid, a lipid capable of reducing aggregation, a cationic lipid of the present invention, and optionally, a sterol. The lipid particle may further include a therapeutic agent such as a nucleic acid. | 2022-04-28 |
20220125928 | COMPOSITIONS AND METHODS FOR STABILIZING PROTEIN-CONTAINING FORMULATIONS - The present invention relates to use of certain cholate surfactant comprising compositions for enhancing the storage stability of antibodies and other proteins in therapeutically useful formulations. | 2022-04-28 |
20220125929 | PHARMACEUTICAL COMPOSITION CONTAINING ANIONIC DRUG, AND PREPARATION METHOD THEREFOR - Disclosed are a pharmaceutical composition for anionic drug delivery, and a preparation method therefor, the pharmaceutical composition for anionic drug delivery containing: an anionic drug as an active ingredient; a cationic compound; an amphiphilic block copolymer; and a polylactate, wherein the anionic drug formed a complex with the cationic lipid, and the complex is encapsulated within a micelle structure formed by the amphiphilic block copolymer and the polylactate. | 2022-04-28 |
20220125930 | SYSTEM AND METHOD FOR FABRICATION OF LARGE, POROUS DRUG-SILK MATERIALS USING CRYOGRANULATION - A method of making drug-eluting regenerated silk fibroin particles using cryogranulation. The method has a first step of injecting a mixture into a super-cooled fluid, the mixture including regenerated silk fibroin and at least one medicament. A second step of incubating the drug-eluting particles in the super-cooled fluid to promote cryogelation may also be used. The size distribution, morphology, and cross-linking efficiency of the particles can depend on several controllable variable, such as starting concentrations of cross-linking agents and silk fibroin in the mixture, the injection pressure, and the temperature of the super-cooled fluid. | 2022-04-28 |
20220125931 | PHARMACEUTICAL PREPARATION WITH CURCUMINOIDS NANOPARTICLES AND A METHOD FOR PRODUCING THE SAME - The present disclosure relates to a pharmaceutical composition having a mixture containing curcuminoids as at least one of the active therapeutic agents. Generally, the mixture comprises 4-8% by weight of purified curcuminoids; 20-35% by weight of an oil phase; 25-35% by weight of a co-solvent; and 40-50% by weight of a surfactant. Preferably, the purified curcuminoids in the mixture has an average size of about 19 nm or at least half of the curcuminoids carried in the mixture has particle size not exceeding 19 nm. | 2022-04-28 |
20220125932 | STABLE CANNABINOID FORMULATIONS - The present invention is generally directed to substantially pure cannabidiol, stable cannabinoid pharmaceutical formulations, and methods of their use. | 2022-04-28 |
20220125933 | LIPID PRODRUGS OF JAK INHIBITORS AND USES THEREOF - The present invention provides lymphatic system-directing lipid prodrugs, pharmaceutical compositions thereof, methods of producing such prodrugs and compositions, and methods of improving the bioavailability or other properties of a therapeutic agent that comprises part of the lipid prodrug. The present invention also provides methods of treating a disease, disorder, or condition such as those disclosed herein, comprising administering to a patient in need thereof a disclosed lipid prodrug or a pharmaceutical composition thereof. | 2022-04-28 |
20220125934 | LINKERS - The present invention relates to linkers for connecting a carrier molecule to a therapeutic molecule to form a conjugate, in particular linkers formed of amino acids such as glutamic acid, succinic acid, and gamma-aminobutyric acid. The present invention further relates to a conjugate comprising a linker of the invention, and the use of said conjugate in the treatment of various diseases. | 2022-04-28 |
20220125935 | COMPOSITION FOR PREVENTING OR TREATING ATOPIC DERMATITIS COMPRISING SKIN-PENETRATING NUCLEIC ACID COMPLEX AS EFFECTIVE COMPONENT - The present invention relates to a composition for preventing or treating skin diseases, comprising a skin-penetrating nucleic acid complex as an effective component, and more specifically, to a pharmaceutical composition or a cosmetic composition for preventing, alleviating, or treating atopic dermatitis, comprising a skin-penetrating nucleic acid complex in which a carrier peptide nucleic acid and a bioactive nucleic acid targeting TLR2 or IL-4Rα are connected by complementary binding. The skin-penetrating nucleic acid complex according to the present invention, in which the carrier peptide nucleic acid and the bioactive nucleic acid targeting TLR2 or IL-4Rα are connected by complementary binding, has high skin permeation and skin retention, and thus is useful in the prevention, alleviation or treatment of skin diseases such as atopic dermatitis. | 2022-04-28 |
20220125936 | AMIDE-BASED PROTEOLYSIS MODULATORS OF B-RAPIDLY ACCELERATED FIBROSARCOMA (BRAF) AND ASSOCIATED USES - The present application relates to novel compounds of Formula (I) containing a E3 ubiquitin ligase binding moiety linked to a Raf protein kinase binding moiety. The present application also includes methods and uses of the compounds, for example, for inhibiting and/or degrading V600E mutant B-Raf. I | 2022-04-28 |
20220125937 | ZWITTERIONIC POLYMER-INSULIN COMPOSITIONS AND RELATED METHODS - Glucose-responsive zwitterionic polymer-insulin-saccharide compositions are provided according to aspects of the present disclosure which include a zwitterionic polymer, an insulin moiety, a saccharide moiety, and a saccharide binding molecule. Methods of use of glucose-responsive zwitterionic polymer-insulin-saccharide compositions according to aspects of the present disclosure include administration to human patients to alleviate conditions, such as diabetes, which are responsive to administration of insulin. | 2022-04-28 |
20220125938 | COMPOSITIONS AND METHODS FOR DISASSEMBLING AMYLOID FIBRILS - The present disclosure provides multivalent polymer-peptide conjugate compositions capable of breaking already formed amyloid fibrils. Also provided are methods of treating a subject having or suspected of having Alzheimer's disease by administering a therapeutically effective amount of these multivalent polymer-peptide conjugate compositions. | 2022-04-28 |
20220125939 | METHOD OF PREPARING PEGYLATED BIOMOLECULES HAVING CONTROLLABLE BINDING SITES - The present invention discloses a method of preparing PEGylated biomolecules having controllable binding sites, including the following steps: (1) binding a blocker to a biomolecule; (2) PEGylating the biomolecule; and (3) separating the blocker from the biomolecule. In another aspect, the present invention discloses a method for preparing PEGylated IL-2 having controllable binding sites, including the following steps: (1) binding IL-2 to an IL-2α receptor, closing the a binding site of the IL-2; (2) PEGylating, coupling PEG with the IL-2; and (3) separating the IL-2 from the IL-2α receptor. By regulating IL-2 binding sites and a PEGylation process only adding one or two polyethylene glycols, the IL-2 is caused to selectively bind to an IL-2R βγ-type receptor. | 2022-04-28 |
20220125940 | CO-AGONISTS AT GLP-1 AND GIP RECEPTORS SUITABLE FOR ORAL DELIVERY - Peptide co-agonists of the human GLP-1 and GIP receptors suitable for oral delivery, including long-acting derivatives, and their medical use in treatment and/or prevention of obesity, diabetes, and/or liver diseases are described. | 2022-04-28 |
20220125941 | Hemiasterlin Derivative and Antibody-Drug Conjugate Thereof - A compound represented by formula (1): | 2022-04-28 |
20220125942 | METHODS OF USING ANTI-CD79b IMMUNOCONJUGATES TO TREAT FOLLICULAR LYMPHOMA - Provided herein are methods of treating B-cell proliferative disorders (such as Follicular Lymphoma “FL”) using immunoconjugates comprising anti-CD79b antibodies in combination with an immunomodulatory agent (such as lenalidomide) and an anti-CD20 antibody (such as obinutuzumab or rituximab). | 2022-04-28 |
20220125943 | ANTIBODY-PYRROLOBENZODIAZEPINE DERIVATIVE CONJUGATE - The present invention provides a novel antibody-pyrrolodiazepine derivative and a novel antibody-pyrrolodiazepine derivative conjugate using the same, and a novel CLDN6 and/or CLDN9 antibody. | 2022-04-28 |
20220125944 | ANTIBODY-DRUG CONJUGATE AND USE THEREOF - The present invention relates to a novel compound comprising a galactose trigger moiety and cyclopropabenzindole (CBI), and an antibody-drug conjugate prepared by using same. | 2022-04-28 |
20220125945 | COMPOSITIONS AND METHODS FOR INDUCING ANTIGEN-SPECIFIC TOLERANCE - Erythrocyte-binding moieties coupled to tolerizing antigens are described. Provided for are peptidic ligands having sequences that specifically bind, or as antibodies or fragments thereof that provide specific binding, to erythrocytes. The erythrocyte-binding moieties may be prepared as molecular fusions with therapeutic agents, tolerizing antigens, or targeting peptides. Immunotolerance may be created by use of the fusions and choice of an antigen on a substance for which tolerance is desired. | 2022-04-28 |
20220125946 | RECOMBINANT ADENOVIRUSES CARRYING TRANSGENES - Disclosed herein are recombinant adenoviruses with one or more nucleotide sequences inserted between two viral transcription units, formulations comprising the recombinant adenoviruses, and methods of treatment using the recombinant adenoviruses. In some embodiments, the one or more nucleotide sequences are inserted in an IX-E2 insertion site and/or an L5-E4 insertion site. | 2022-04-28 |
20220125947 | COMPOSITIONS AND METHODS FOR MODULATING DELTA GAMMA CHAIN MEDIATED IMMUNITY - Provided herein, in certain aspects, are antibodies that bind to T cell receptor (TCR) Vγ9 (TRGV9), TCR Vδ2 (TRDV2), or the TCR gamma/delta constant region (TRGDC), as well as recombinant cells containing the vectors, and compositions comprising the antibodies. Methods of making and using the antibodies are also provided. | 2022-04-28 |
20220125948 | COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF RETINOPATHIES - The present invention provides compositions and methods related to the cell surface protein CRB1 for the treatment of retinopathies in a subject, as well as systems and kits employing such compositions. | 2022-04-28 |
20220125949 | GENE THERAPY FOR TREATING MUCOPOLYSACCHARIDOSIS TYPE II - A suspension useful for AAV9-mediated intrathecal and/or systemic delivery of an expression cassette containing a hIDS gene is provided herein. Also provided are methods and kits containing these vectors and compositions useful for treating Hunter syndrome and the symptoms associated with Hunter syndrome. | 2022-04-28 |
20220125950 | AAV GENE THERAPY FOR TREATING NEPHROTIC SYNDROME - The present invention provides an adeno-associated virus (AAV) vector gene therapy for use in treating a monogenic form of nephrotic syndrome, wherein the AAV vector comprises a NS-associated transgene and minimal nephrin promoter NPHS1 or podocin promoter NPHS2. | 2022-04-28 |
20220125951 | MICROENVIRONMENT SENSORS TO REGULATE ENGINEERED GENE EXPRESSION - Some embodiments of the methods and compositions provided herein relate to transgenes comprising regulatory elements capable of inducing specific transcription of an operably-linked therapeutic payload in a cell in an in vivo microenvironment. In some embodiments, the regulatory elements are responsive to endogenous stimuli of the microenvironment. In some embodiments, the regulatory elements are response to stimuli from chimeric receptors in the cell. | 2022-04-28 |
20220125952 | DELIVERY OF POLYNUCLEOTIDES USING RECOMBINANT AAV9 - The present invention relates to Adeno-associated virus 9 methods and materials useful for systemically delivering polynucleotides across the blood brain barrier. Accordingly, the present invention also relates to methods and materials useful for systemically delivering polynucleotides to the central and peripheral nervous systems. The present invention also relates to Adeno-associated virus type 9 methods and materials useful for intrathecal delivery of polynucleotides. Use of the methods and materials is indicated, for example, for treatment of lower motor neuron diseases such as spinal muscle atrophy and amyotrophic lateral sclerosis as well as Pompe disease and lysosomal storage disorders. Use of the methods and materials is also indicated, for example, for treatment of Rett syndrome. | 2022-04-28 |
20220125953 | Synthetic Scaffolds for Metastasis Detection - Provided herein are synthetic scaffolds engineered to function as a pre-metastatic niche to detect metastasis. In particular, synthetic scaffolds described herein provide detection of the earliest events in metastasis, thereby enabling treatment of metastasis before the disease burden increases. | 2022-04-28 |
20220125954 | IMPLANTS AND BIODEGRADABLE TISSUE MARKERS - Implantable materials may be used in an iatrogenic site. Applications include radioopaque materials for fiducial marking. | 2022-04-28 |
20220125955 | PER-ORAL NEGATIVE CONTRAST AGENT FOR ABDOMINAL IMAGING - An edible negative contrast agent for CT imaging of the gastrointestinal tract intended for oral intake. The contrast agent is a fluid, aqueous foam displaying a CT density contrast value in the range −300 to −800 HU and having a consistency of 7 to 12 cm as measured with Bostwick consistometer. The contrast agent comprises an aqueous continuous liquid phase having a pH of 6.5 to 8.0 and gas bubbles dispersed in the continuous aqueous liquid phase. The aqueous continuous liquid phase comprises a surfactant, the surfactant being a protein, a hydrocolloid acting as foam stabilizer, a buffering agent, and water. | 2022-04-28 |
20220125956 | COMPOSITIONS AND METHODS TO DETECT GLUA1 IN BRAIN AND TO IDENTIFY THE PRESENCE OF GLUA1-MEDIATED PTSD - The present invention provides compositions and methods for detecting GluA1, as a subunit protein and/or as a GluA1-containing, GluA2-lacking AMPAR complex. The invention further provides composition and methods for detecting and/or diagnosing PTSD. The invention further relates to compositions that can be detected using radiological imaging techniques, and processes for performing such imaging techniques using the compositions, to identify elevated GluA1 expression or activity in a subject, which is a biological marker of PTSD. | 2022-04-28 |
20220125957 | METHODS OF TREATING CANCER - The disclosure pertains to drug delivery conjugates for targeted therapy. The disclosure relates to methods of treating PSMA expressing cancers with a combination of compounds of the formulas I-Lu or Ia-Lu, and I-Ac or Ia-Ac. The disclosure also relates to methods of treating PSMA-expressing cancers with a combination of compounds of the formulas I-Lu or Ia-Lu, and I-Ac or Ia-Ac in N patients where stable disease results after treatment with a combination of compounds of the formulas I-Lu or Ia-Lu, and I-Ac or Ia-Ac. | 2022-04-28 |